| ID | Peptide Seq | Site Residue | Position in Peptide | Position in Protein |
|---|---|---|---|---|
| 10006031 | SRGVVMLNR | S | 1 | 104 |
| 10006032 | ESGSLSPEHGPVVVHCSAGIGR | S | 2 | 201 |
| 10006033 | GAQAASPAK | S | 6 | 386 |
| ID | Method | Analytical Throughput | Ambiguity | Species | Sample Type | Condition | log2Ratio | P Value | Data Source PMID | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| 10006031 | MS, site-directed mutagenesis | LTP | unambiguous | human | HepG2 cells | None | 26402673 | No peptides info. provided; the peptide sequence is inferredfrom tryptic cleavage | ||
| 10006032 | MS, site-directed mutagenesis | LTP | unambiguous | human | HepG2 cells | None | 26402673 | No peptides info. provided; the peptide sequence is inferredfrom tryptic cleavage | ||
| 10006033 | MS, site-directed mutagenesis | LTP | unambiguous | human | HepG2 cells | None | 26402673 | No peptides info. provided; the peptide sequence is inferredfrom tryptic cleavage |
| ID | Peptide Seq | Site Residue | Position in Peptide | Position in Protein | Method | Analytical Throughput | Ambiguity | Species | Sample Type | Data Source PMID | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10006031 | SRGVVMLNR | S | 1 | 104 | MS, site-directed mutagenesis | LTP | unambiguous | human | HepG2 cells | 26402673 | No peptides info. provided; the peptide sequence is inferredfrom tryptic cleavage |
| 10006032 | ESGSLSPEHGPVVVHCSAGIGR | S | 2 | 201 | MS, site-directed mutagenesis | LTP | unambiguous | human | HepG2 cells | 26402673 | No peptides info. provided; the peptide sequence is inferredfrom tryptic cleavage |
| 10006033 | GAQAASPAK | S | 6 | 386 | MS, site-directed mutagenesis | LTP | unambiguous | human | HepG2 cells | 26402673 | No peptides info. provided; the peptide sequence is inferredfrom tryptic cleavage |